Which of the 20,000+ potential protein drug targets
are most promising for allosteric control?
AI-enabled target scoring for modality fit, disease-relevance and competition to rapidly narrow the search.
One target in clinical stage plus more in the pipeline (as of 9/2021).
Clinical-stage biotech company pioneering targeted protein degradation.
”Learning about the biology behind this new technology is fascinating – and so is pioneering the AI toolchain to help bring it to the clinic.”